Literature DB >> 24166495

SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

M Trautmann1, E Sievers2, S Aretz3, D Kindler2, S Michels2, N Friedrichs2, M Renner4, J Kirfel5, S Steiner5, S Huss2, A Koch6, R Penzel4, O Larsson7, A Kawai8, S Tanaka9, H Sonobe10, A Waha11, P Schirmacher4, G Mechtersheimer4, E Wardelmann2, R Büttner2, W Hartmann2.   

Abstract

Synovial sarcoma is a high-grade soft tissue malignancy characterized by a specific reciprocal translocation t(X;18), which leads to the fusion of the SS18 (SYT) gene to one of three SSX genes (SSX1, SSX2 or SSX4). The resulting chimeric SS18-SSX protein is suggested to act as an oncogenic transcriptional regulator. Despite multimodal therapeutic approaches, metastatic disease is often lethal and the development of novel targeted therapeutic strategies is required. Several expression-profiling studies identified distinct gene expression signatures, implying a consistent role of Wnt/β-catenin signaling in synovial sarcoma tumorigenesis. Here we investigate the functional and therapeutic relevance of Wnt/β-catenin pathway activation in vitro and in vivo. Immunohistochemical analyses of nuclear β-catenin and Wnt downstream targets revealed activation of canonical Wnt signaling in a significant subset of 30 primary synovial sarcoma specimens. Functional aspects of Wnt signaling including dependence of Tcf/β-catenin complex activity on the SS18-SSX fusion proteins were analyzed. Efficient SS18-SSX-dependent activation of the Tcf/β-catenin transcriptional complex was confirmed by TOPflash reporter luciferase assays and immunoblotting. In five human synovial sarcoma cell lines, inhibition of the Tcf/β-catenin protein-protein interaction significantly blocked the canonical Wnt/β-catenin signaling cascade, accompanied by the effective downregulation of Wnt targets (AXIN2, CDC25A, c-MYC, DKK1, CyclinD1 and Survivin) and the specific suppression of cell viability associated with the induction of apoptosis. In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/β-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels. In summary, SS18-SSX-induced Wnt/β-catenin signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression, representing a potential molecular target for the development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166495     DOI: 10.1038/onc.2013.443

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review.

Authors:  Leandro Blas; Javier Roberti
Journal:  Curr Urol Rep       Date:  2021-03-11       Impact factor: 3.092

2.  Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics.

Authors:  Vickie Y Jo; Christopher D M Fletcher
Journal:  Head Neck Pathol       Date:  2016-06-20

3.  ATR Is a Therapeutic Target in Synovial Sarcoma.

Authors:  Samuel E Jones; Emmy D G Fleuren; Jessica Frankum; Asha Konde; Chris T Williamson; Dragomir B Krastev; Helen N Pemberton; James Campbell; Aditi Gulati; Richard Elliott; Malini Menon; Joanna L Selfe; Rachel Brough; Stephen J Pettitt; Wojciech Niedzwiedz; Winette T A van der Graaf; Janet Shipley; Alan Ashworth; Christopher J Lord
Journal:  Cancer Res       Date:  2017-10-16       Impact factor: 12.701

4.  Epigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma.

Authors:  Pingyu Zhang; Raphael E Pollock
Journal:  Cancer Cell Microenviron       Date:  2014

5.  The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Authors:  Ana Banito; Xiang Li; Aimée N Laporte; Jae-Seok Roe; Francisco Sanchez-Vega; Chun-Hao Huang; Amanda R Dancsok; Katerina Hatzi; Chi-Chao Chen; Darjus F Tschaharganeh; Rohit Chandwani; Nilgun Tasdemir; Kevin B Jones; Mario R Capecchi; Christopher R Vakoc; Nikolaus Schultz; Marc Ladanyi; Torsten O Nielsen; Scott W Lowe
Journal:  Cancer Cell       Date:  2018-03-01       Impact factor: 31.743

6.  Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Authors:  Theodore S Nowicki; Ryan Akiyama; Rong Rong Huang; I Peter Shintaku; Xiaoyan Wang; Paul C Tumeh; Arun Singh; Bartosz Chmielowski; Christopher Denny; Noah Federman; Antoni Ribas
Journal:  Cancer Immunol Res       Date:  2016-12-30       Impact factor: 11.151

Review 7.  Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.

Authors:  Torsten O Nielsen; Neal M Poulin; Marc Ladanyi
Journal:  Cancer Discov       Date:  2015-01-22       Impact factor: 39.397

Review 8.  Targeting the WNT Signaling Pathway in Cancer Therapeutics.

Authors:  David Tai; Keith Wells; John Arcaroli; Chad Vanderbilt; Dara L Aisner; Wells A Messersmith; Christopher H Lieu
Journal:  Oncologist       Date:  2015-08-25

Review 9.  Current management of pediatric soft tissue sarcomas.

Authors:  Surasak Sangkhathat
Journal:  World J Clin Pediatr       Date:  2015-11-08

10.  The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma.

Authors:  Jianming Tang; Huijuan Shi; Hui Li; Tiantian Zhen; Yu Dong; Fenfen Zhang; Yang Yang; Anjia Han
Journal:  Tumour Biol       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.